Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy
Abstract Objective Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on the neurodevelopmental outcomes is debated. The aim of this study was to evaluate...
Saved in:
| Main Authors: | Jordane Louis, Natalia Doudka, Marie‐Solenne Félix, Adeline Spiga Ghata, Camille Espanet, Romain Guilhaumou, Mathieu Milh, Laurent Villard |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Epilepsia Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/epi4.70087 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of early epileptic encephalopathy caused by new mutation at W218C in KCNQ2 and review literature
by: Juhua Yang, et al.
Published: (2025-06-01) -
Clinical features of developmental and epileptic encephalopathy caused by <i>KCNQ2</i> gene mutation
by: А. G. Malov, et al.
Published: (2023-12-01) -
KCNQ2 Encephalopathy and Neonatal Seizures
by: J Gordon Millichap
Published: (2011-11-01) -
Biophysical and structural mechanisms of epilepsy-associated mutations in the S4-S5 Linker of KCNQ2 channels
by: Inn-Chi Lee, et al.
Published: (2025-12-01) -
Mint Tea (Pennyroyal) Epileptic Encephalopathy
by: J Gordon Millichap
Published: (1996-12-01)